World Conference on Lung Cancer
TP53 mutations drive resistance and lower survival in ALK-rearranged lung cancer with distinct RB1 co-mutation effects.
A recent study revealed ALK+ NSCLC patients face psychological, professional, and lifestyle challenges despite longer surviva
WCLC included abstracts on metastatic non-small cell lung cancer focused on antibody-drug conjugate and cytotoxic therapy.
By targeting the molecules that cancer cells need to proliferate, these treatments cause less damage to healthy cells.
Researchers created a clinicopathologic relapse risk score and linked it with AI-derived immune signatures.
Identifying reliable biomarkers to predict therapeutic benefit remains a critical unmet need.
Exhaled breath analysis has emerged as a noninvasive tool with potential diagnostic and predictive applications in oncology.
Stereotactic body radiation therapy is the standard of care for patients with medically inoperable stage I/II NSCLC.
Patients treated with chemotherapy experienced the highest 3-year overall survival, followed by chemoimmunotherapy.
180 Mount Airy Road Suite 205
Basking Ridge, NJ 07920
Connect
The content of this site is intended for healthcare professionals.
© 2025 Physician’s Weekly, a Formedics PropertyAny views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Physician’s Weekly, their employees, and affiliates.